Proprietary, highly efficient and scalable linDNA (linear DNA, the product of PCR) manufacturing process for use in nucleic acid-based therapies. Learn how LineaRx is the common denominator of next-generation therapies.
– Separately, LineaRx Announces Successful Expression In Vitro of Vaccine Candidate Encapsulated with Lipid Nanoparticles – STONY BROOK, N.Y. July 25, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, today announced the publication of a manuscript containing data demonstrating that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular […]
– Industry Leaders Will Learn How LinearDNA Can Significantly Improve RNA Manufacturing Speed, Simplicity, and Scalability in Comparison to Plasmid DNA – STONY BROOK, N.Y. – July 22, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied […]
STONY BROOK, N.Y. – June 29, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, announced the formal launch of business development initiatives to expand the biotherapeutics industry’s awareness of the LinearDNA™ platform (the “platform”) as an alternative to current plasmid-based (pDNA) production processes used in the […]
Powering nucleic acid-based therapies into the future with LinearDNATM—The global demand for DNA continues to rise at a breakneck pace. This trend began with the introduction of redirected cell and gene therapies and was supercharged by the success of mRNA COVID-19 vaccines.
STONY BROOK, N.Y. and ROME, ITALY – June 6, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. (“EvviVax”), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform […]
DNA-based vaccines represent a simple, safe and promising strategy for harnessing the immune system to fight infectious diseases as well as various forms of cancer.
STONY BROOK, N.Y. and TORONTO, CANADA – March 14, 2022 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc. (“Spindle Biotech”), a company focused on the development of a novel, high yield, and low-cost RNA production systems, today announced that the two companies have executed […]
Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]
– First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen – – Targeted Vaccines Elicit a Therapeutic Immune Response in Animal Cancer Models – – LinearDNA Vaccines Elicits Strong Antigen-specific Immune Responses and Significantly Reduces Tumor Growth – – Manuscript Summarizing Findings Posted to Preprint Server and Submitted for Peer-Reviewed Publication – STONY BROOK, […]